Therapeutic targeting of malignant glioma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2014-09-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1871520614666140825105145PMID 25175690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype.

  2013influential reference
• EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

  2013cited by this paper
• Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

  2012cited by this paper
• Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin.

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth after chemotherapy

  2012influential reference
• Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.

  2012cited by this paper
• Clinical trials with immunotherapy for high-grade glioma.

  2012cited by this paper
• Elevating SOX2 Levels Deleteriously Affects the Growth of Medulloblastoma and Glioblastoma Cells

  2012cited by this paper
• Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma†

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth following chemotherapy

  2012cited by this paper
• A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

  2012cited by this paper
• Dendritic cell vaccines.

  2012cited by this paper
• Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

  2012cited by this paper
• Glioma stem cells: their role in chemoresistance.

  2012cited by this paper
• Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells

  2012cited by this paper
• Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

  2012cited by this paper
• CD133 negative cancer stem cells in glioblastoma.

  2011cited by this paper
• Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions

  2011cited by this paper
• Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

  2011cited by this paper
• Identification of CD133−/Telomeraselow Progenitor Cells in Glioblastoma-Derived Cancer Stem Cell Lines

  2011cited by this paper
• SOX2 expression and amplification in gliomas and glioma cell lines.

  2011cited by this paper
• Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy

  2011influential reference
• Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas

  2011cited by this paper
• Elevated invasive potential of glioblastoma stem cells.

  2011cited by this paper
• Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

  2011cited by this paper
• Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells

  2011cited by this paper
• Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model

  2010influential reference
• NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐functional network with GLI1 and p53

  2010cited by this paper
• Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.

  2010cited by this paper
• Recent Insights into PDGF‐Induced Gliomagenesis

  2010cited by this paper
• L1CAM malfunction in the nervous system and human carcinomas

  2010influential reference
• microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

  2010influential reference
• A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

  2010cited by this paper
• Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

  2010cited by this paper
• Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis

  2010cited by this paper
• Hypoxia inducible factors in cancer stem cells

  2010cited by this paper
• Inhibition of Notch Signaling in Glioblastoma Targets Cancer Stem Cells via an Endothelial Cell Intermediate

  2010influential reference
• IGFBP2 promotes glioma tumor stem cell expansion and survival.

  2010cited by this paper
• Integrin alpha 6 regulates glioblastoma stem cells.

  2010cited by this paper
• Residual tumor cells are unique cellular targets in glioblastoma

  2010cited by this paper
• Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting

  2010influential reference
• Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.

  2010cited by this paper
• The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

  2010cited by this paper
• Immune therapeutic targeting of glioma cancer stem cells

  2010cited by this paper
• Notch Activity Levels Control the Balance between Quiescence and Recruitment of Adult Neural Stem Cells

  2010cited by this paper
• Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

  2010cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

  2009cited by this paper
• Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.

  2009cited by this paper
• The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors

  2009influential reference
• Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

  2009influential reference
• Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

  2009cited by this paper
• TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

  2009cited by this paper
• Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

  2009cited by this paper
• Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.

  2009cited by this paper
• NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts

  2009cited by this paper
• Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α

  2009influential reference
• Hypoxia enhances the generation of induced pluripotent stem cells.

  2009cited by this paper
• Notch Promotes Radioresistance of Glioma Stem Cells

  2009cited by this paper
• SOX2 Silencing in Glioblastoma Tumor‐Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity

  2009cited by this paper
• A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers

  2009cited by this paper
• PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

  2009influential reference
• PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges

  2009cited by this paper
• Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors*

  2009cited by this paper
• The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype

  2009cited by this paper
• Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors

  2009cited by this paper
• Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors.

  2009influential reference
• Enhanced MDR1 Expression and Chemoresistance of Cancer Stem Cells Derived from Glioblastoma

  2009cited by this paper
• Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma.

  2009cited by this paper
• P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

  2008cited by this paper
• Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas

  2008cited by this paper
• c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells

  2008cited by this paper
• Notch signaling in leukemias and lymphomas.

  2008cited by this paper
• Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

  2008cited by this paper
• Molecular Cancer BioMed Central

  2008cited by this paper
• CD133 Is a Marker of Bioenergetic Stress in Human Glioma

  2008cited by this paper
• Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma

  2008influential reference
• Temozolomide preferentially depletes cancer stem cells in glioblastoma.

  2008cited by this paper
• Targeting cancer stem cells through L1CAM suppresses glioma growth.

  2008cited by this paper
• Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

  2008cited by this paper
• Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells*

  2008cited by this paper
• GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME

  2008cited by this paper
• Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition

  2008cited by this paper
• Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.

  2007cited by this paper
• Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.

  2007cited by this paper
• HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.

  2007cited by this paper
• MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells

  2007cited by this paper
• CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

  2007cited by this paper
• Experimental anti‐angiogenesis causes upregulation of genes associated with poor survival in glioblastoma

  2007cited by this paper
• Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy

  2007cited by this paper
• TGF-beta in neural stem cells and in tumors of the central nervous system

  2007cited by this paper
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  2007cited by this paper
• Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy

  2007influential reference
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling

  2006cited by this paper
• CXCR4 Inhibition Synergizes with Cytotoxic Chemotherapy in Gliomas

  2006cited by this paper
• Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells.

  2006cited by this paper
• Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy

  2006cited by this paper
• Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

  2006cited by this paper
• In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas

  2006cited by this paper

• Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM)

  2025cites this paper
• Therapeutic Potential of Selenium in Glioblastoma

  2021cites this paper
• The HIF1α/JMY pathway promotes glioblastoma stem-like cell invasiveness after irradiation

  2020cites this paper
• Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.

  2019cites this paper
• Glioblastoma Multiforme: A Review on Causes, Mechanisms, and Solutions

  2019cites this paper
• MicroRNA-211 expression is down-regulated and associated with poor prognosis in human glioma

  2017cites this paper
• Roles of microRNA-99 family in human glioma

  2016cites this paper
• roles of microrna-99 family in human glioma

  2016cites this paper
• Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.

  2016cites this paper
• Emerging concepts and therapeutics strategies for the treatment of brain tumors.

  2014cites this paper